Literature DB >> 11925618

Effect of L-NAME on nitric oxide and gastrointestinal motility alterations in cirrhotic rats.

Xin Wang1, Yue-Xia Zhong, Zong-You Zhang, Ju Lu, Mei Lan, Ji-Yan Miao, Xue-Gang Guo, Yong-Quan Shi, Yan-Qiu Zhao, Jie Ding, Kai-Cun Wu, Bo-Rong Pan, Dai-Ming Fan.   

Abstract

AIM: To investigate the effect of L-NAME on nitric oxide and gastrointestinal motility alterations in cirrhotic rats.
METHODS: Rats with cirrhosis induced by carbon tetrachloride were randomly divided into two groups, one n =13 receiving 0.5mg.kg(-1) per day of N(G)-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor, for 10 days, whereas the other group (n =13) and control (n =10) rats were administrated the same volume of 9g.L(-1) saline. Half gastric emptying time and 2h residual rate were measured by SPECT, using (99m)Tc-DTPA-labeled barium sulfate as test meal. Gastrointestinal transition time was recorded simultaneously. Serum concentration of nitric oxide (NO) was determined by the kinetic cadmium reduction and colorimetric methods. Immunohistochemical SABC method was used to observe the expression and distribution of three types of nitric oxide synthase (NOS) isoforms in the rat gastrointestinal tract. Western blot was used to detect expression of gastrointestinal NOS isoforms.
RESULTS: Half gastric emptying time and trans-gastrointestinal time were significantly prolonged(124.0 +/- 26.4 min; 33.7 +/- 8.9 min; 72.1 +/- 15.3 min; P<0.01), (12.4 +/- 0.5h; 9.5 +/- 0.3h; 8.2 +/- 0.8h; P<0.01), 2h residual rate was raised in cirrhotic rats than in controls and cirrhotic rats treated with L-NAME (54.9 +/- 7.6%,13.7 +/- 3.2%, 34.9 +/- 10.3%, P<0.01). Serum concentration of NO was significantly increased in cirrhotic rats than in the other groups (8.20 +/- 2.48) micromol.L(-1), (5.94 +/-1.07) micromol.L(-1) and control (5.66 +/- 1.60 micromol.L(-1), P<0.01. NOS staining intensities which were mainly located in the gastrointestinal tissues were markedly lower in cirrhotic rats than in the controls and cirrhotic rats after treated with L-NAME.
CONCLUSION: Gastrointestinal motility was remarkably inhibited in cirrhotic rats, which could be alleviated by L-NAME. Nitric oxide may play an important role in the inhibition of gastrointestinal motility in cirrhotic rats.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11925618      PMCID: PMC4658377          DOI: 10.3748/wjg.v8.i2.328

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  Protective effect of electroacupuncture and moxibustion on gastric mucosal damage and its relation with nitric oxide in rats.

Authors:  Wen-Fen Pei; Guan-Sun Xu; Yong Sun; Shun-Li Zhu; Dao-Qin Zhang
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

2.  Expression of inducible nitric oxide synthase in human gastric cancer.

Authors:  Yu Jun; Guo Fei; Matthias P A Ebert; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

3.  Study of T-lymphocyte subsets, nitric oxide, hexosamine and Helicobacter pylori infection in patients with chronic gastric diseases.

Authors:  Hui Zhang; Shu-Lin Jiang; Xi-Xian Yao
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

4.  Enzymohistochemical study on burn effect on rat intestinal NOS.

Authors:  Qiu-Gui Wang; Li-Ya He; Ye-Wen Chen; Song-Lin Hu
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

5.  Nitric oxide synthase distribution in esophageal mucosa and hemodynamic changes in rats with cirrhosis.

Authors:  Ying-Qiu Huang; Shu-Dong Xiao; De-Zhong Zhang; Jian-Zhong Mo
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

6.  Distribution of nitric oxide synthase in stomach wall in rats.

Authors:  Xi Peng; Jing-Bin Feng; Shi-Liang Wang
Journal:  World J Gastroenterol       Date:  1999-02       Impact factor: 5.742

7.  Hepatic and splanchnic nitric oxide activity in patients with cirrhosis.

Authors:  A I Sarela; F M Mihaimeed; J J Batten; B R Davidson; R T Mathie
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

8.  Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function.

Authors:  A M Madrid; C Hurtado; M Venegas; F Cumsille; C Defilippi
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

9.  A study on relationship of nitric oxide, oxidation, peroxidation, lipoperoxidation with chronic chole-cystitis.

Authors:  Jun-Fu Zhou; Dong Cai; You-Gen Zhu; Jin-Lu Yang; Cheng-Hong Peng; Yang-Hai Yu
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

10.  The impact of chronic hepatitis B viral infection on gastrointestinal motility.

Authors:  C Y Chen; C L Lu; F Y Chang; Y S Huang; F Y Lee; R H Lu; K Lih-Jiun; S D Lee
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-09       Impact factor: 2.566

View more
  4 in total

1.  Effects and mechanism of changes of local neurotransmitters in rats' pylorus and bile reflux to the stomach with stress ulcer.

Authors:  Chen Min; Luo Hesheng; Chen Jihong; Tong Qiaoyun; Li Xianzhen; Shelley Chireyeth
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

2.  Effects of neurotrophins on gastrointestinal myoelectric activities of rats.

Authors:  Ning-Li Chai; Lei Dong; Zong-Fang Li; Ke-Xin Du; Jian-Hua Wang; Li-Kun Yan; Xi-Lin Dong
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

3.  Effects of estradiol on liver estrogen receptor-alpha and its mRNA expression in hepatic fibrosis in rats.

Authors:  Jun-Wang Xu; Jun Gong; Xin-Ming Chang; Jin-Yan Luo; Lei Dong; Ai Jia; Gui-Ping Xu
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

Review 4.  Gastrointestinal Motility Disorders and Their Clinical Implications in Cirrhosis.

Authors:  Eleni Theocharidou; Ameet Dhar; David Patch
Journal:  Gastroenterol Res Pract       Date:  2017-05-11       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.